These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 6413369)
21. Evidence-based focused review of management of hyperviscosity syndrome. Stone MJ; Bogen SA Blood; 2012 Mar; 119(10):2205-8. PubMed ID: 22147890 [No Abstract] [Full Text] [Related]
22. [Blood diseases]. Bottura C Prensa Med Argent; 1966 Sep; 53(39):2358-69. PubMed ID: 4969976 [No Abstract] [Full Text] [Related]
23. [Extracorporeal methods of therapy in lymphatic tumors]. Ryzhko VV; Andreeva NE; Gorodetskiĭ VM; Konovalova VI; Aleksanian MZh; Sinitsina TV Ter Arkh; 1990; 62(7):59-63. PubMed ID: 2123573 [TBL] [Abstract][Full Text] [Related]
24. Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases. Mód A; Füst G; Harsányi V; Natonek K; Poros A; Szabó J; Hollán SR Haematologia (Budap); 1981; 14(1):49-56. PubMed ID: 6454615 [TBL] [Abstract][Full Text] [Related]
25. [Treatment of hematologic diseases with alpha interferon]. Castaigne S Bull Cancer; 1988; 75(9):859-62. PubMed ID: 3207895 [TBL] [Abstract][Full Text] [Related]
26. [Effect of intensive plasmapheresis on the "syndrome of increased viscosity" and blood coagulation system in Waldenstrom's macroglobulinemia]. Mokeeva RA; Zhuravlev VS Probl Gematol Pereliv Krovi; 1969 Mar; 14(3):8-16. PubMed ID: 4981700 [No Abstract] [Full Text] [Related]
27. One year review of the blood cell separator programme. Tan YO; Kueh YK; Suri R; Oon CJ; Ng HW; Goh CN; Ong YW Ann Acad Med Singap; 1981 Jul; 10(3):394-7. PubMed ID: 7332308 [TBL] [Abstract][Full Text] [Related]
28. [Therapeutic value of the cell separator. Review and case reports]. Rossi PL Minerva Med; 1979 Apr; 70(18):1289-98. PubMed ID: 450268 [TBL] [Abstract][Full Text] [Related]
29. Correction of hyperviscosity by apheresis. Zarkovic M; Kwaan HC Semin Thromb Hemost; 2003 Oct; 29(5):535-42. PubMed ID: 14631553 [TBL] [Abstract][Full Text] [Related]
30. Compelling splenectomy in medically compromised patients. Bergin JJ; Zuck TF; Miller RE Ann Surg; 1973 Dec; 178(6):761-8. PubMed ID: 4519051 [No Abstract] [Full Text] [Related]
32. Applications and limitations of hemapheresis. Silvergleid AJ Annu Rev Med; 1983; 34():69-89. PubMed ID: 6344778 [TBL] [Abstract][Full Text] [Related]
34. [Interferon therapy in hematologic neoplasms]. Schwarzinger I; Bettelheim P; Lechner K Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854 [TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of plasmapheresis on the PF-0.5 blood separator in patients with paraproteinemic hemoblastoses]. Abdullaev OM; Postnikov AA; Prigozhina TA; Likhovetskaia ZM; Mokeeva RA Ter Arkh; 1987; 59(10):77-81. PubMed ID: 2448887 [TBL] [Abstract][Full Text] [Related]
36. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation. Reinhart WH; Lutolf O; Nydegger UR; Mahler F; Straub PW J Lab Clin Med; 1992 Jan; 119(1):69-76. PubMed ID: 1727909 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic apheresis: when things go wrong. Torloni AS; Lumadue J; Zubair A J Clin Apher; 2012; 27(3):168-71. PubMed ID: 22504899 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Blum W; Porcu P Semin Thromb Hemost; 2007 Jun; 33(4):350-4. PubMed ID: 17525892 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic apheresis: where we've been and where we are going. Vogler WR Prog Clin Biol Res; 1982; 106():1-13. PubMed ID: 6757935 [TBL] [Abstract][Full Text] [Related]
40. Practical considerations for planning a therapeutic apheresis procedure. Shelat SG Am J Med; 2010 Sep; 123(9):777-84. PubMed ID: 20541168 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]